Navigation Links
Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
Date:8/3/2009

BEIJING, Aug. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine and, during the three-day observation of safety, the preliminary tests on the A/H1N1 influenza vaccine have indicated that the vaccine is safe and reliable in humans.

The clinical trial began on July 22, 2009 and a total of 1,614 volunteers, including 101 elders, 706 adults, 404 juvenile and 403 children, had received the first shot of the vaccine through July 25. During the three-day safety observation period, none of the volunteers participating in Sinovac's clinical tests exhibited any signs of severe adverse reactions. Total adverse event rate is 11.8%, which is similar to seasonal influenza vaccine. The adverse events were all mild and transient. The most common symptom is pain at the site of injection.

This clinical trial is organized by China's Center for Disease Control (CDC), and undertaken by Beijing CDC. The Ministry of Health (MOH) and State Food and Drug Administration (SFDA) are paying great attention to this clinical trial. Deputy Director General of MOH Disease Control Department, Donglou Xiao, Director of SFDA Registration Section, Wei Zhang, and other relevant experts visited the clinical site to inspect the clinical study. In June 2009, Sinovac announced that the Ministry of Health had made an initial order of 4 million doses of Panflu, which is expected to be delivered by the end of September.

As usual, Sinovac's seasonal influenza vaccine has been released by China SFDA and officially launched to the market at the end of July 2009.

About Sinovac

Sinovac Biotech Ltd. is a China
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Sinovac Biotech Holds Annual General Meeting
10. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech (Cayman) ... capability and technology platform company serving the pharmaceutical, biotechnology, ... ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), a ... with 20 years of operations in ... companies have signed an agreement whereby WuXi,s Laboratory Testing ...
(Date:8/25/2015)... 2015 Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... joined the company as Chief Operating Officer. Winham, who brings ... technical experience, will report directly to HLI,s CEO, J. ... role as COO, Winham will be responsible for managing all ... all facility operations. HLI currently has three locations in ...
(Date:8/25/2015)... Aug. 25, 2015  InformedDNA, a leading provider ... has been awarded Certification in Utilization Management by ... NCQA is a private, non-profit organization ... a wide range of healthcare organizations. It also ... performance. "Our achievement of the NCQA ...
(Date:8/25/2015)... PRUSSIA, Pa. , Aug. 25, 2015   ... has been enrolled in its Phase II/III clinical study ... company,s recombinant fusion protein linking coagulation factor VIIa with ... hemophilia A or B who have developed an inhibitor ... study will enroll approximately 54 male patients, the first ...
Breaking Biology Technology:WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2InformedDNA Achieves NCQA Utilization Management Certification 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 4
... 100,000 doses can be manufactured per week , , ... that today it commenced manufacturing of a vaccine to protect ... estimates that it can produce 100,000 doses this week and ... called PanBlok(R), is made using PSC,s proprietary baculovirus and insect ...
... , SEATTLE, June 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. ... today announced the appointment of Scott Peterson, Ph.D., ... In this position, Dr. Peterson will be responsible ... development activities that will support the advancement of ...
... , SAN DIEGO, June 15 Hollis-Eden Pharmaceuticals, ... development of a new class of small molecule compounds based ... directors has appointed James M. Frincke Ph.D. as President and ... elected to the company,s board of directors. , , ...
Cached Biology Technology:Commercial Manufacturing of H1N1 'Swine Flu' Vaccine Underway 2Oncothyreon appoints Scott Peterson as Vice President of Research and Development 2Oncothyreon appoints Scott Peterson as Vice President of Research and Development 3Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 2Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 3
(Date:8/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... Smart Card Alliance and the EMV Migration Forum.  ... Smart Card Alliance Latin America (SCALA) Chapter provides NXT-ID, ... thought leaders promoting adoption of smart card technology. ...
(Date:8/18/2015)... DUBLIN , Aug. 17, 2015 ... the addition of the "Global Biometric Authentication ... Application - Estimation & Forecast, 2015-2020" report ... biometric authentication and identification systems market is expected ... from 2015 to 2020 and generate over $25 ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... sense of touch, researchers have shown. A study, by Dr ... at the University of Surrey, has found that Bacillus mycoides ... forces and curvature in the medium on which it,s growing. ... as revealed in the journal PLOS ONE , could signal ...
... in German . ... More precise tests may allow allergy sufferers more freedom of food ... out by the Helmholtz Centre for Environmental Research (UFZ), the University ... examined patients with a Nile perch allergy. Being allergic to Nile ...
... - December 10, 2013 Researchers at the Icahn ... strain of influenza the virus that causes the flu ... even after it develops resistance to antiviral medications. The finding was ... Nature Communications . It is not uncommon for ...
Cached Biology News:The garden microbe with a sense of touch 2Each food fish can cause specific allergies 2Each food fish can cause specific allergies 3Mount Sinai researchers say new strain of bird flu packs a punch even after becoming drug-resistant 2